RT Journal Article
T1 A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.
A1 Correll, C U
A1 Agid, Ofer
A1 Crespo-Facorro, Benedicto
A1 de Bartolomeis, Andrea
A1 Fagiolini, Andrea
A1 Seppälä, Niko
A1 Howes, Oliver D
K1 Cognition
K1 Algorithms
K1 Schizophrenia
K1 Antipsychotic Agents
AB Treatment-resistant schizophrenia (TRS) will affect about one in three patients with schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be treated as soon as possible to improve their chances of achieving remission. Despite its effectiveness, concern over side effects, monitoring requirements, and inexperience with prescribing often result in long delays that can expose patients to unnecessary risks and compromise their chances of achieving favorable long-term outcomes. We critically reviewed the literature on clozapine use in TRS, focusing on guidelines, systematic reviews, and algorithms to identify strategies for improving clozapine safety and tolerability. Based on this, we have provided an overview of strategies to support early initiation of clozapine in patients with TRS based on the latest evidence and our clinical experience, and have summarized the key elements in a practical, evidence-based checklist for identifying and managing patients with TRS, with the aim of increasing confidence in prescribing and monitoring clozapine therapy.
PB Adis International Ltd
YR 2022
FD 2022-06-27
LK http://hdl.handle.net/10668/21652
UL http://hdl.handle.net/10668/21652
LA en
NO Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppälä N, et al. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs. 2022 Jul;36(7):659-679.
DS RISalud
RD Apr 11, 2025